信件：炎症性肠病药物与严重 COVID-19 结局相关的风险-来自英国 PREPARE-IBD 多中心队列研究的令人安心的见解。
Letter: risk of severe COVID-19 outcomes associated with inflammatory bowel disease medications-reassuring insights from the United Kingdom PREPARE-IBD multicentre cohort study.
机构信息
Newcastle upon Tyne, UK.
Hull, UK.
出版信息
Aliment Pharmacol Ther. 2021 Jun;53(11):1236-1240. doi: 10.1111/apt.16349.
Abstract
LINKED CONTENT This article is linked to Taxonera et al paper. To view this article, visit https://doi.org/10.1111/apt.15804
摘要
关联内容 本文链接到 Taxonera 等人的论文。要查看本文，请访问 https://doi.org/10.1111/apt.15804
相似文献
1
Letter: risk of severe COVID-19 outcomes associated with inflammatory bowel disease medications-reassuring insights from the United Kingdom PREPARE-IBD multicentre cohort study.信件：炎症性肠病药物与严重 COVID-19 结局相关的风险-来自英国 PREPARE-IBD 多中心队列研究的令人安心的见解。
Aliment Pharmacol Ther. 2021 Jun;53(11):1236-1240. doi: 10.1111/apt.16349.
2
Maintenance therapy with infliximab or vedolizumab in IBD is not associated with increased SARS-CoV-2 seroprevalence: UK experience in the 2020 pandemic.英夫利昔单抗或维多珠单抗用于炎症性肠病的维持治疗与严重急性呼吸综合征冠状病毒2（SARS-CoV-2）血清阳性率增加无关：英国在2020年大流行中的经验
Gut. 2021 Dec;70(12):2398-2400. doi: 10.1136/gutjnl-2021-324116. Epub 2021 Feb 12.
3
Safety of biologics in inflammatory bowel disease patients with COVID-19.COVID-19 患者炎症性肠病中生物制剂的安全性。
Int J Colorectal Dis. 2021 Sep;36(9):2051-2055. doi: 10.1007/s00384-021-03977-9. Epub 2021 Jun 15.
4
Editorial: IBD medications during the COVID-19 pandemic-are they safe to use?社论：COVID-19 大流行期间的 IBD 药物——它们的使用安全吗？
Aliment Pharmacol Ther. 2021 Jul;54(2):208-209. doi: 10.1111/apt.16459.
5
Inflammatory bowel disease and SARS-CoV-2 pandemic: current knowledge and recommendations.炎症性肠病与 SARS-CoV-2 大流行：现有知识和建议。
Scand J Gastroenterol. 2021 Jun;56(6):656-660. doi: 10.1080/00365521.2021.1902561. Epub 2021 Mar 25.
6
Interim analysis of a multicenter registry study of COVID-19 patients with inflammatory bowel disease in Japan (J-COSMOS).日本 COVID-19 合并炎症性肠病患者多中心登记研究的中期分析（J-COSMOS）。
J Gastroenterol. 2022 Mar;57(3):174-184. doi: 10.1007/s00535-022-01851-1. Epub 2022 Jan 28.
7
Low prevalence of SARS-CoV-2 infection in inflammatory bowel disease.炎症性肠病中 SARS-CoV-2 感染的低流行率。
Eur Rev Med Pharmacol Sci. 2021 Mar;25(5):2418-2424. doi: 10.26355/eurrev_202103_25283.
8
Outcomes of COVID-19 in Patients with Inflammatory Bowel Disease: Comparison with Household Members and the Role of IBD Medications.COVID-19 患者的结局：与家庭成员的比较及 IBD 药物的作用。
Arch Iran Med. 2022 Jan 1;25(1):17-25. doi: 10.34172/aim.2022.04.
9
Commenting on the Letter (Completing the Picture in Egypt: Response to "Inflammatory Bowel Diseases in Egypt During the COVID-19 Pandemic").对该信函的评论（完善埃及的情况：对“新冠疫情期间埃及的炎症性肠病”的回应）
Inflamm Bowel Dis. 2021 Apr 15;27(5):e66. doi: 10.1093/ibd/izab009.
10
Impact of immunosuppressants on SARS-CoV-2 infection in elderly patients with inflammatory bowel disease.免疫抑制剂对老年炎症性肠病患者感染 SARS-CoV-2 的影响。
Aging Clin Exp Res. 2021 Aug;33(8):2355-2359. doi: 10.1007/s40520-021-01917-9. Epub 2021 Jun 23.
引用本文的文献
1
SARS-CoV-2 infection in patients with inflammatory bowel disease: comparison between the first and second pandemic waves.SARS-CoV-2 感染炎症性肠病患者：第一波和第二波大流行期间的比较。
BMC Gastroenterol. 2023 Jul 5;23(1):230. doi: 10.1186/s12876-023-02841-0.
2
Inflammatory bowel disease and COVID-19 outcomes: a meta-analysis.炎症性肠病与 COVID-19 结局：荟萃分析。
Sci Rep. 2022 Dec 9;12(1):21333. doi: 10.1038/s41598-022-25429-2.
3
Risk of adverse outcomes in inflammatory bowel disease patients infected with SARS-CoV-2: a systematic review and meta-analysis.SARS-CoV-2 感染对炎症性肠病患者不良结局风险的系统评价和荟萃分析。
Int J Colorectal Dis. 2022 Nov;37(11):2277-2289. doi: 10.1007/s00384-022-04265-w. Epub 2022 Oct 22.
4
Treatment adaptations and outcomes of patients experiencing inflammatory bowel disease flares during the early COVID-19 pandemic: the PREPARE-IBD multicentre cohort study.在 COVID-19 大流行早期经历炎症性肠病发作的患者的治疗调整和结局：PREPARE-IBD 多中心队列研究。
Aliment Pharmacol Ther. 2022 Nov;56(10):1460-1474. doi: 10.1111/apt.17223. Epub 2022 Oct 5.
5
Impact of biologics and small molecules for inflammatory bowel disease on COVID-19-related hospitalization and mortality: A systematic review and meta-analysis.生物制剂和小分子药物对炎症性肠病患者COVID-19相关住院率和死亡率的影响：一项系统评价和荟萃分析
JGH Open. 2022 Mar 20;6(4):241-250. doi: 10.1002/jgh3.12728. eCollection 2022 Apr.
6
Predictors of Covid-19 vaccination acceptance in IBD patients: a prospective study.炎症性肠病患者对 COVID-19 疫苗接种接受度的预测因素：一项前瞻性研究。
Eur J Gastroenterol Hepatol. 2021 Dec 1;33(1S Suppl 1):e1042-e1045. doi: 10.1097/MEG.0000000000002320.
7
Outcomes and Long-Term Effects of COVID-19 in Patients with Inflammatory Bowel Diseases - A Danish Prospective Population-Based Cohort Study with Individual-Level Data.炎症性肠病患者 COVID-19 的结局和长期影响 - 一项丹麦前瞻性基于人群的队列研究，具有个体水平数据。
J Crohns Colitis. 2022 Jun 24;16(5):757-767. doi: 10.1093/ecco-jcc/jjab192.
本文引用的文献
1
Effect of IBD medications on COVID-19 outcomes: results from an international registry.IBD 药物对 COVID-19 结局的影响：来自国际注册研究的结果。
Gut. 2021 Apr;70(4):725-732. doi: 10.1136/gutjnl-2020-322539. Epub 2020 Oct 20.
2
Increased incidence of systemic serious viral infections in patients with inflammatory bowel disease associates with active disease and use of thiopurines.炎症性肠病患者全身性严重病毒感染发生率增加与疾病活动和使用硫嘌呤类药物相关。
United European Gastroenterol J. 2019 Nov 14;8(3):303-313. doi: 10.1177/2050640619889763. Print 2020 Apr.
3
Baseline Disease Activity and Steroid Therapy Stratify Risk of COVID-19 in Patients With Inflammatory Bowel Disease.基线疾病活动度和类固醇治疗对炎症性肠病患者感染新型冠状病毒肺炎的风险进行分层。
Gastroenterology. 2020 Oct;159(4):1541-1544.e2. doi: 10.1053/j.gastro.2020.05.066. Epub 2020 May 29.
4
Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry.皮质类固醇，而不是 TNF 拮抗剂，与炎症性肠病患者 COVID-19 不良结局相关：来自国际登记处的结果。
Gastroenterology. 2020 Aug;159(2):481-491.e3. doi: 10.1053/j.gastro.2020.05.032. Epub 2020 May 18.
5
2019 novel coronavirus disease (COVID-19) in patients with inflammatory bowel diseases.2019 新型冠状病毒病（COVID-19）合并炎症性肠病患者。
Aliment Pharmacol Ther. 2020 Jul;52(2):276-283. doi: 10.1111/apt.15804. Epub 2020 Jun 7.
6
Outcomes of COVID-19 in 79 patients with IBD in Italy: an IG-IBD study.意大利 IBD 患者中 79 例 COVID-19 的结局：一项 IG-IBD 研究。
Gut. 2020 Jul;69(7):1213-1217. doi: 10.1136/gutjnl-2020-321411. Epub 2020 Apr 30.
7
British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemic.英国胃肠病学会在 COVID-19 大流行期间炎症性肠病管理指南。
Gut. 2020 Jun;69(6):984-990. doi: 10.1136/gutjnl-2020-321244. Epub 2020 Apr 17.
8
Risk of Serious and Opportunistic Infections Associated With Treatment of Inflammatory Bowel Diseases.炎症性肠病治疗相关的严重和机会性感染风险。
Gastroenterology. 2018 Aug;155(2):337-346.e10. doi: 10.1053/j.gastro.2018.04.012. Epub 2018 Apr 12.
9
Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT™ registry.克罗恩病患者的严重感染和死亡率：TREAT™ 注册研究的 5 年以上随访结果。
Am J Gastroenterol. 2012 Sep;107(9):1409-22. doi: 10.1038/ajg.2012.218. Epub 2012 Aug 14.
Zotero 插件